Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Drug Deal Can Only Help VIVUS, Inc. (VVUS) So Much

VIVUS, Inc. (NASDAQ:VVUS) has found an Italian to help it out. The biotech announced Tuesday that Menarini has agreed to market VIVUS’ erectile dysfunction drug Spedra in more than 40 European countries plus Australia and New Zealand.


The Italian pharma is paying VIVUS, Inc. (NASDAQ:VVUS) about $21 million upfront and another $30 million — at current exchange rates — within the first year of the launch. VIVUS, Inc. (NASDAQ:VVUS) is also due undisclosed royalties and potentially another $102 million at current exchange rates in milestones and other payments over the life of the agreement.

Menarini has more of the men’s sexual health spectrum covered since it also sells Priligy, a treatment for premature ejaculation. The ability for the company to promote more than one drug to doctors shouldn’t be underestimated. Having multiple drugs can help a sales rep get in the door and increases efficiency, which should result in higher profits.

Small key to unlocking value
No doubt, potential sales of Spedra outside the U.S. are important. First-quarter sales of Pfizer Inc. (NYSE:PFE)‘s Viagra outside the U.S. were 47% of total Viagra sales. In the first quarter, Eli Lilly & Co. (NYSE:LLY) actually sold more of its erectile dysfunction drug Cialis outside of the U.S. than inside it.

But Menarini has its work cut out for it. While Spedra is arguably a better drug than Viagra and Cialis because of its earlier onset, Menarini will have to compete with generic versions of Viagra, which Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) recently launched in Europe.

VIVUS, Inc. (NASDAQ:VVUS) also has to find a partner inside the U.S., which might be a little more challenging. Pfizer Inc. (NYSE:PFE) and Eli Lilly & Co. (NYSE:LLY) are clearly out as are Bayer and GlaxoSmithKline plc (ADR) (NYSE:GSK), which co-market the less-popular Levitra. That doesn’t leave too many large pharmas to partner with, and I’m not sure there’s a specialty pharma in the U.S. like Menarini that has a large enough primary care physician sales force.

Less important long term
The upfront cash from Menarini and hopefully a marketing partner in the U.S., where it will go by Stendra, will help keep the company afloat. But the VIVUS, Inc. (NASDAQ:VVUS)’ long-term success ultimately has a lot more to do with its obesity drug Qsymia than how well its partner for Spedra/Stendra is able to market the drug.

VIVUS, Inc. (NASDAQ:VVUS) should really consider following its model for Spendra and find a marketing partner for Qsymia, perhaps rolling it into a deal for the U.S. rights to Stendra. It’s true that the company would have to give up quite a bit of upside, but a partner could potentially make up for that through increasing sales by giving Qsymia substantially more promotion than VIVUS’ tiny sale force is able to muster.

The article Drug Deal Can Only Help VIVUS So Much originally appeared on is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.